[HTML][HTML] Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures
…, E Klann, MR Angiolieri, JW Johnson… - Journal of Biological …, 2000 - ASBMB
Oxidative stress can trigger neuronal cell death and has been implicated in several chronic
neurological diseases and in acute neurological injury. Oxidative toxicity can be induced by …
neurological diseases and in acute neurological injury. Oxidative toxicity can be induced by …
Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine
SE Kotermanski, JW Johnson - Journal of Neuroscience, 2009 - Soc Neuroscience
N-Methyl-d-aspartate receptors (NMDARs) mediate interneuronal communication and are
broadly involved in nervous system physiology and pathology ( Dingledine et al., 1999 ). …
broadly involved in nervous system physiology and pathology ( Dingledine et al., 1999 ). …
NR2 subunit‐dependence of NMDA receptor channel block by external Mg2+
A Qian, AL Buller, JW Johnson - The Journal of physiology, 2005 - Wiley Online Library
The vital roles played by NMDA receptors in CNS physiology depend critically on powerful
voltage‐dependent channel block by external Mg 2+ (Mg 2+ o ). NMDA receptor channel …
voltage‐dependent channel block by external Mg 2+ (Mg 2+ o ). NMDA receptor channel …
Mechanism of action of memantine
JW Johnson, SE Kotermanski - Current opinion in pharmacology, 2006 - Elsevier
Memantine is a clinically useful drug in many neurological disorders, including Alzheimer's
disease. The principal mechanism of action of memantine is believed to be the blockade of …
disease. The principal mechanism of action of memantine is believed to be the blockade of …
Evolution in damage control for exsanguinating penetrating abdominal injury
JW Johnson, VH Gracias, CW Schwab… - Journal of Trauma …, 2001 - journals.lww.com
Objective Damage control (DC) has proven valuable in exsanguinated patients. The purpose
of this study was to quantify and qualify the impact of current damage control principles …
of this study was to quantify and qualify the impact of current damage control principles …
Recent insights into the mode of action of memantine and ketamine
JW Johnson, NG Glasgow, NV Povysheva - Current opinion in …, 2015 - Elsevier
Highlights • Memantine and ketamine block open NMDAR channels via apparently similar
mechanisms. • Memantine is a very well-tolerated drug approved for treatment of Alzheimer's …
mechanisms. • Memantine is a very well-tolerated drug approved for treatment of Alzheimer's …
Memantine binding to a superficial site on NMDA receptors contributes to partial trapping
…, JT Wood, JW Johnson - The Journal of …, 2009 - Wiley Online Library
Although many nervous system disorders are associated with N‐methyl‐d‐aspartate (NMDA)
receptor overactivation, pharmacological inhibition of NMDA receptors has typically …
receptor overactivation, pharmacological inhibition of NMDA receptors has typically …
Mechanism of differential control of NMDA receptor activity by NR2 subunits
N-methyl-d-aspartate (NMDA) receptors (NMDARs) are a major class of excitatory neurotransmitter
receptors in the central nervous system. They form glutamate-gated ion channels that …
receptors in the central nervous system. They form glutamate-gated ion channels that …
Trapping channel block of NMDA-activated responses by amantadine and memantine
…, E Aizenman, JW Johnson - Journal of …, 1997 - journals.physiology.org
… Blanpied, Thomas A., Faye Boeckman, Elias Aizenman, and Jon W. Johnson. Trapping … of
Pittsburgh Central Research Development Award to JWJohnson, by a Mellon Fellowship and …
Pittsburgh Central Research Development Award to JWJohnson, by a Mellon Fellowship and …
Memantine and ketamine differentially alter NMDA receptor desensitization
…, NV Povysheva, AM Azofeifa, JW Johnson - Journal of …, 2017 - Soc Neuroscience
Memantine and ketamine are clinically useful NMDA receptor (NMDAR) open channel blockers
that inhibit NMDARs with similar potency and kinetics, but display vastly different clinical …
that inhibit NMDARs with similar potency and kinetics, but display vastly different clinical …